Mary J. Wilkinson
Experienced in Endometrial Stromal Sarcoma

Dr. Mary J. Wilkinson

Oncology
Johns Hopkins Medicine
Sibley Memorial Hospital
Washington, DC 
Offers Telehealth

Experienced in Endometrial Stromal Sarcoma
Johns Hopkins Medicine
Sibley Memorial Hospital
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Mary Wilkinson is a medical oncologist caring for patients with breast cancer and gyn malignancies. Dr. Wilkinson sees patients primarily at Sibley Memorial Hospital in Washington DC. She also serves as clinical director of the Under Armour Breast Health Innovation Center at the Sidney Kimmel Comprehensive Cancer Center. Dr. Wilkinson received her undergraduate degree in electrical engineering from Rice University and earned her M.D. from Stanford University School of Medicine. She completed her residency and performed a fellowship in hematology and oncology at the University of California, San Francisco. Dr. Wilkinson joined the Johns Hopkins faculty in 2019. Prior to joining Johns Hopkins, Dr. Wilkinson was director of breast cancer research at the Inova Schar Cancer Institute and president of Medical Oncology Hematology Associates of Northern Virginia. She also spent time on the faculty at Georgetown University and the University of California, San Francisco. Dr. Wilkinson is a member of the American Society of Clinical Oncology.

Dr. Wilkinson is rated as an Experienced provider by MediFind in the treatment of Endometrial Stromal Sarcoma. Her top areas of expertise are Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Inflammatory Breast Cancer.

Her clinical research consists of co-authoring 8 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
University of California, San Francisco, School of Medicine, Internal Medicine, 1986
Specialties
Oncology
Licenses
Internal Medicine in VA
Board Certifications
American Board Of Internal Medicine
Fellowships
University of California, San Francisco, School of Medicine, Oncology and Hematology, 1989
Hospital Affiliations
Sibley Memorial Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Sibley Memorial Hospital
Building B, Washington, DC 20016
Call: 202-660-6500

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


12 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Phase I Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Phase I Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Enrollment Status: Completed
Publish Date: October 24, 2024
Intervention Type: Drug
Study Drugs: Fostamatinib, Paclitaxel
Study Phase: Phase 1
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drugs: GSK525762, Fulvestrant
Study Phase: Phase 1
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer
Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: Cyclophosphamide, Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim
Study Phase: Phase 2
An Exploratory Pilot Study of Vitamin D Supplementation in Women With DCIS and/or LCIS
An Exploratory Pilot Study of Vitamin D Supplementation in Women With DCIS and/or LCIS
Enrollment Status: Terminated
Publish Date: December 16, 2020
Intervention Type: Drug
Study Phase: Early Phase 1
View 11 Less Clinical Trials

8 Total Publications

Prospective Integration of Patient Preferences into Adjuvant Therapy Decisions for Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer.
Prospective Integration of Patient Preferences into Adjuvant Therapy Decisions for Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer.
Journal: Practical radiation oncology
Published: May 13, 2025
View All 8 Publications
Similar Doctors
Edward J. Tanner
Distinguished in Endometrial Stromal Sarcoma
Dr. Edward J. Tanner
Oncology | Obstetrics and Gynecology
Distinguished in Endometrial Stromal Sarcoma
Dr. Edward J. Tanner
Oncology | Obstetrics and Gynecology

Johns Hopkins Health Care & Surgery Center — Bethesda

Bethesda, MD 
 (2.2 miles away)
202-243-5295
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Edward Tanner, M.D., is a professor of gynecologic oncology in the Johns Hopkins Medicine Department of Gynecology and Obstetrics and the medical director for women’s health in the Johns Hopkins National Capital Region. Dr. Tanner is an internationally recognized expert in gynecologic surgery and is known for his surgical skills, compassionate bedside manner, leadership and teaching abilities. Dr. Tanner’s clinical interests include surgical management of advanced gynecologic cancers, including radical debulking surgery for ovarian cancer, as well as minimally invasive surgery for early-stage female cancers. He is particularly focused on developing innovative techniques that reduce complications and speed recovery time. His research interests include sentinel lymph node mapping in endometrial and cervical cancers, exploring ways to reduce complications for patients having surgery for advanced ovarian cancer, robotic single-site surgery and identifying new treatments for patients with uterine sarcoma. He has authored more than 80 articles in peer-reviewed medical journals and has lectured nationally and internationally on sentinel lymph node techniques, uterine sarcoma and surgical innovations for gynecologic cancer. He is the chapter author of “Surgery for Endometrial Cancer” in Telinde’s Operative Gynecology, the definitive textbook for gynecologic surgery techniques in the United States. Dr. Tanner is a member of the NRG Corpus Committee, which develops clinical trials for uterine cancer on behalf of the National Cancer Institute. A Maryland native, Dr. Tanner received his medical degree from the University of Alabama at Birmingham before returning to Baltimore to complete his residency in gynecology and obstetrics at The Johns Hopkins Hospital. He completed a fellowship in gynecologic oncology at Memorial Sloan Kettering Cancer Center, where he was among the first fellows to complete an extensive training program in robotic surgery for gynecologic cancers. Dr. Tanner has served as a faculty member at The Johns Hopkins Hospital as well as the Marcia Stenn Professor and chief of gynecologic oncology at Northwestern University in Chicago. Having served as the gynecologic oncology fellowship program director at both The Johns Hopkins Hospital and Northwestern Memorial Hospital, Dr. Tanner taught the next generation of gynecologic surgeons and health care leaders. Dr. Tanner is rated as a Distinguished provider by MediFind in the treatment of Endometrial Stromal Sarcoma. His top areas of expertise are Endometrial Stromal Sarcoma, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Hernia Surgery, and Oophorectomy.

Distinguished in Endometrial Stromal Sarcoma
Dr. Annette Bicher
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Endometrial Stromal Sarcoma
Dr. Annette Bicher
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Capital Womens Care LLC

2301 Research Blvd, Suite 215, 
Rockville, MD 
 (8.3 miles away)
301-424-3444
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Annette Bicher is a Gynecologic Oncologist and an Oncologist in Rockville, Maryland. Dr. Bicher is rated as a Distinguished provider by MediFind in the treatment of Endometrial Stromal Sarcoma. Her top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Ovarian Carcinosarcoma, Hernia Surgery, and Ureteroscopy. Dr. Bicher is currently accepting new patients.

Distinguished in Endometrial Stromal Sarcoma
Dr. Dwight D. Im
Gynecologic Oncology | Oncology
Distinguished in Endometrial Stromal Sarcoma
Dr. Dwight D. Im
Gynecologic Oncology | Oncology

St Paul Place Specialists, Inc.

301 Saint Paul St, 
Baltimore, MD 
 (33.6 miles away)
Languages Spoken:
English, Korean
See accepted insurances
Accepting New Patients

Dwight Im is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Im is rated as a Distinguished provider by MediFind in the treatment of Endometrial Stromal Sarcoma. His top areas of expertise are Rectocele, Endometrial Cancer, Endometrial Stromal Sarcoma, Hysterectomy, and Oophorectomy. Dr. Im is currently accepting new patients.

VIEW MORE ENDOMETRIAL STROMAL SARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wilkinson's expertise for a condition
ConditionClose
    • Distinguished
    • Angiosarcoma
      Dr. Wilkinson is
      Distinguished
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Breast Cancer
      Dr. Wilkinson is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Inflammatory Breast Cancer
      Dr. Wilkinson is
      Distinguished
      . Learn about Inflammatory Breast Cancer.
      See more Inflammatory Breast Cancer experts
    • Paget Disease of the Breast
      Dr. Wilkinson is
      Distinguished
      . Learn about Paget Disease of the Breast.
      See more Paget Disease of the Breast experts
    • Advanced
    • Endometrial Cancer
      Dr. Wilkinson is
      Advanced
      . Learn about Endometrial Cancer.
      See more Endometrial Cancer experts
    • Malignant Mixed Mullerian Tumor
      Dr. Wilkinson is
      Advanced
      . Learn about Malignant Mixed Mullerian Tumor.
      See more Malignant Mixed Mullerian Tumor experts
    • Ovarian Carcinosarcoma
      Dr. Wilkinson is
      Advanced
      . Learn about Ovarian Carcinosarcoma.
      See more Ovarian Carcinosarcoma experts
    • Virilizing Ovarian Tumor
      Dr. Wilkinson is
      Advanced
      . Learn about Virilizing Ovarian Tumor.
      See more Virilizing Ovarian Tumor experts
    • Experienced
    • Adult Soft Tissue Sarcoma
      Dr. Wilkinson is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Anal Cancer
      Dr. Wilkinson is
      Experienced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Appendix Cancer
      Dr. Wilkinson is
      Experienced
      . Learn about Appendix Cancer.
      See more Appendix Cancer experts
    • Breast Cancer in Men
      Dr. Wilkinson is
      Experienced
      . Learn about Breast Cancer in Men.
      See more Breast Cancer in Men experts
    • Cervical Cancer
      Dr. Wilkinson is
      Experienced
      . Learn about Cervical Cancer.
      See more Cervical Cancer experts
    • Colorectal Cancer
      Dr. Wilkinson is
      Experienced
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.